A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Inclusion Criteria:

• Body Mass Index ≥ 25 and < 40 kg/m^2
• No serious medical problems or chronic diseases, specifically no type I or type II diabetes

Exclusion Criteria:

• Another disorder that contributes to gastrointestinal symptoms
• History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
• History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
• Exposure to any investigational medication within the past 60 days